Barrington Keeps Their Buy Rating on Option Care Health (OPCH)

Barrington analyst Michael Petusky maintained a Buy rating on Option Care Health today and set a price target of $42.00.

Claim 70% Off TipRanks Premium

• Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
• Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential

According to TipRanks, Petusky is a 2-star analyst with an average return of 0.7% and a 44.81% success rate. Petusky covers the Healthcare sector, focusing on stocks such as DENTSPLY SIRONA, Haemonetics, and US Physical Therapy.

In addition to Barrington, Option Care Health also received a Buy from TipRanks – Google’s Google Medical – Care Facilities in a report issued today. However, on January 13, TipRanks – OpenAI downgraded Option Care Health (NASDAQ: OPCH) to a Hold.

Based on Option Care Health’s latest earnings release for the quarter ending September 30, the company reported a quarterly revenue of $1.44 billion and a net profit of $51.82 million. In comparison, last year the company earned a revenue of $1.28 billion and had a net profit of $53.86 million

Based on the recent corporate insider activity of 46 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of OPCH in relation to earlier this year. Most recently, in November 2025, Harry Jansen Kraemer, a Director at OPCH bought 38,000.00 shares for a total of $987,240.00.